U.S. Oil and Gas Stock News

If you are wondering whether Astec Industries is still reasonably priced after its recent run, the stock's current valuation story is worth a closer look. The share price sits at US$54.87 after a 3.9% gain over the last 7 days, a 5.2% decline over 30 days, and returns of 22.9% year to date and 52.0% over 1 year, with a 3 year return of 41.6% and a 5 year return of a 22.9% decline. Recent coverage around Astec Industries has focused on its position within the capital goods space and how...

What recent returns say about Leggett & Platt (LEG) Leggett & Platt (LEG) has drawn fresh attention after a mixed stretch of performance, with a 0.4% decline over the past day, a 2.5% gain over the past week, and weaker month and past 3 months returns. In this context, investors are weighing how the current US$10.10 share price and the company’s value score of 5 line up with its recent revenue and net income figures as well as its longer term track record. See our latest analysis for Leggett...

Signet Jewelers (NYSE:SIG) approved an almost 10% increase to its quarterly dividend, marking a fifth consecutive year of higher shareholder payouts. The company also recently completed another tranche of its ongoing share repurchase program. These twin capital return actions arrive at a time when other coverage of NYSE:SIG has centered on earnings results and valuation. Signet Jewelers, the owner of jewelry retail banners such as Kay, Zales, and Jared, sits at the intersection of...

M-tron Industries (MPTI) closed FY 2025 with fourth quarter revenue of US$14.2 million and basic EPS of US$1.16, alongside trailing twelve month revenue of US$54.4 million and EPS of US$2.94 that frame the latest print in a broader earnings context. Over the past six reported quarters, the company has seen quarterly revenue range from US$12.8 million to US$14.2 million and basic EPS move between US$0.55 and US$1.16, giving you a clear view of how the top line and EPS have tracked into this...

DXC Technology (DXC) has just earned a spot on Fortune's America's Most Innovative Companies list, reflecting its recent AI focused launches. Investors are weighing this recognition against ongoing concerns about sales trends and capital allocation. See our latest analysis for DXC Technology. DXC's recent recognition for its AI efforts comes after a mixed stretch for shareholders, with a 1-day share price return of 3.36% and 7-day share price return of 3.00% contrasting with a 1-year total...

If you are wondering whether Monster Beverage is fairly priced or if the market is missing something, this article walks through the key numbers that matter for you as a shareholder or potential buyer. At a recent close of US$73.21, the stock has seen a 14.4% decline over the last 30 days, while the 1 year return stands at 25.0% and the 5 year return at 60.3%. Recent price moves have put more attention on what might be driving sentiment around Monster Beverage. Wider investor focus on large...

CubeSmart (CUBE) has been on investors’ radar after a recent stretch of mixed returns, highlighted by a roughly 9% decline over the past month alongside a modest gain in the past 3 months. See our latest analysis for CubeSmart. At a share price of US$36.20, CubeSmart’s recent 7 day and 30 day share price returns of roughly 6% and 9% declines contrast with a modestly positive year to date move and a 5 year total shareholder return of about 17%. This suggests momentum has softened even as...

Chewy (CHWY) has just put fresh numbers on the table for FY 2026, with Q3 revenue of US$3.1b and basic EPS of US$0.14, set against trailing 12 month revenue of US$12.6b and EPS of US$0.50. Over recent quarters the company has seen revenue move from US$2.9b in Q2 FY 2025 to US$3.1b in Q3 FY 2026. Over the same period, quarterly basic EPS has ranged from US$0.01 to US$0.70. This gives investors plenty to think about around the consistency of earnings and the pressure on margins. See our full...

Why the supermajority vote change at Public Service Enterprise Group matters Public Service Enterprise Group (PEG) plans to ask stockholders on April 21, 2026 to approve amendments removing supermajority voting requirements from its Certificate of Incorporation and By-Laws. This shift puts voting power more directly in shareholder hands. See our latest analysis for Public Service Enterprise Group. At a share price of US$81.07, Public Service Enterprise Group has a 1-day share price return of...

AGI (NYSE:AGBK) reported record-breaking profits and a 73% increase in its active customer base, alongside expansion of its credit portfolio. The company highlighted continued rollout of its hybrid digital and physical Smart Hub model across Brazil. Management positioned AGI among Brazil’s most efficient and profitable financial institutions and emphasized gains in financial access for underserved communities. AGI, trading as NYSE:AGBK, operates as a financial institution in Brazil with a...

Investors may be wondering whether Palvella Therapeutics at around US$120 a share is still offering value, or if most of the easy gains are already on the table. The stock is up 5.7% over the last 7 days and 20.1% year to date, with a very strong 333.7% return over the past year that may indicate shifting expectations and risk perceptions. Recent attention around Palvella Therapeutics has focused on its position in the biotech space and how the market is reassessing smaller, high potential...

Telesat (NasdaqGS:TSAT) disclosed that its auditor raised substantial doubt about the company’s ability to continue as a going concern in its latest Form 20-F filing. The company also announced plans to add military Ka-band spectrum to its Lightspeed low Earth orbit satellite constellation to support defense requirements. Both developments point to rising pressure on Telesat’s funding profile alongside a clearer push toward government and defense users. Telesat operates in satellite...

Setting the scene: Blaize Holdings's FY 2025 earnings snapshot Blaize Holdings (BZAI) just closed FY 2025 with fourth quarter revenue of US$23.8 million and basic EPS of US$0.03 loss, against trailing twelve month revenue of US$38.6 million and EPS of US$1.98 loss, alongside very large reported year over year revenue growth of 2,386%. The company has seen quarterly revenue move from US$0.001 million in Q4 FY 2024 to US$23.8 million in Q4 FY 2025. Over that span, EPS has ranged from US$1.61...

Wondering if Live Nation Entertainment at around US$154.92 a share still offers value or if most of the upside is already reflected in the price? This breakdown will help you frame that question clearly. The stock has had a mixed recent run, with a 1% decline over the last week and a 2.1% decline over the last month. It is still sitting on a 6.6% year to date gain and a 22.2% return over the last year, alongside a 125.8% return over three years and an 83.0% return over five years. Recent...

This article examines whether Zimmer Biomet Holdings, trading at around US$87.64, appears to be a bargain or a value trap by exploring what the current price may be implying about the stock. The share price has declined 1.6% over the past week, 11.9% over the past month, and 20.0% over the last year, which can influence how the market views both its risk and potential. Recent coverage has focused on how Zimmer Biomet fits within the broader medical equipment space and how investors are...

A shareholder proposal giving investors the right to act by written consent has been submitted at BorgWarner ahead of the upcoming annual meeting. BorgWarner's board has recommended a vote against the proposal, creating a clear split between management and the proponent. The outcome could influence how NYSE:BWA shareholders exercise governance rights between annual meetings. BorgWarner, trading as NYSE:BWA, is entering the annual meeting with governance in focus and a share price of $56.12...

How Novo Nordisk’s recent performance sets up the current valuation debate Novo Nordisk (NYSE:NVO) has recently seen weak share price performance, with negative returns over the past month, past 3 months and year, putting fresh attention on how its current valuation lines up with fundamentals. See our latest analysis for Novo Nordisk. Recent trading has been weak, with a 30 day share price return of 8.33% and a year to date share price return of 30.65%. The 1 year total shareholder return of...

AI powered autonomous agents such as Anthropic's Claude are emerging as cross platform tools that can handle complex workflows typically managed by enterprise software. Investors are starting to question how this could affect the role of traditional application layer providers, including Manhattan Associates (NasdaqGS:MANH), particularly around pricing power and profitability. This development has recently drawn more attention, yet it has not been a core focus of recent coverage that...

Q3 2026 Earnings Snapshot Cintas (CTAS) has just reported Q3 2026 results with quarterly revenue of about US$2.8b and basic EPS of US$1.23, giving investors a fresh read on how the business is tracking this year. Over recent quarters the company has seen revenue move from US$2.50b in Q1 2025 to US$2.80b in Q2 2026, while basic EPS has shifted from US$1.12 to US$1.23, with trailing twelve month net profit margins around 17.5% helping to frame the quality of those earnings. See our full...

Daktronics (DAKT) is back in the spotlight after announcing three fresh major league baseball projects, including a new Mariners Fire TV outfield board in Seattle and large center field displays in Phoenix and Chicago. See our latest analysis for Daktronics. The recent major league baseball wins sit against a mixed share price backdrop, with a 7 day share price return of 5.88%, a 30 day share price return of 22.11% and a 1 year total shareholder return of 69.73%. This indicates that longer...

Wondering if Alkermes at around US$29.37 is a bargain or already pricing in its prospects? This article walks through how the numbers stack up so you can judge the value for yourself. The stock has returned 8.0% over the last 7 days, while the 30 day return is an 8.8% decline, with year to date performance at 3.9% and a 12.8% decline over the past year. Recent coverage has focused on Alkermes as a listed US pharmaceuticals and biotech name, putting attention on how investors are weighing its...

Epsilon Energy (EPSN) has just posted its FY 2025 numbers with third quarter revenue of about US$9.0 million and basic EPS of US$0.05, set against trailing twelve month revenue of US$45.7 million and EPS of US$0.27 that came alongside 11.2% earnings growth and a trailing net margin of 12.9% compared with 17% a year earlier. Over recent quarters the company has seen revenue move from US$7.3 million in Q2 2024 to US$16.2 million in Q1 2025, then to US$9.0 million in Q3 2025. Quarterly EPS has...

BioStem Technologies (OTCPK:BSEM) appointed Jodi Ungrodt as a new member of its Board of Directors and Chair of the Audit Committee. The company completed the acquisition of BioTissue Holdings Inc.'s surgical and wound assets, including a national sales force. The transaction expands BioStem's commercial reach into hospital settings and broadens its product portfolio. BioStem Technologies, trading at $4.92, sits at an interesting point in its share price history, with a 25.9% return year to...

If you are wondering whether AMETEK at around US$215 per share looks expensive or offers value, it is helpful to separate price action from underlying worth. The stock has seen mixed moves recently, with a 1.2% gain over the last 7 days, a 7.0% decline over 30 days, and returns of 3.0% year to date, 22.5% over the past year, 54.4% over 3 years, and 74.2% over 5 years. These moves come alongside a steady stream of company updates and industry commentary that keep AMETEK on many investors'...